Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00565058 · ClinicalTrials.gov registry record · Phase 2
Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)
A Phase 2 study, sponsored by Aptose Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00565058 is a Phase 2 study that has completed, run by Aptose Biosciences. The registered enrollment target is 27 participants.
The verdict
NCT00565058, a Phase 2 study, has completed, sponsored by Aptose Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is a Phase II trial conducted at multiple centers for evaluation of the pharmacodynamic activity and the overall response rate contributed by the combination agents of GTI-2040 and High Dose Cytarabine (HiDAC) in Refractory and Relapsed Acute Myeloid Leukemia (AML).
Interventions
- BIOLOGICAL GTI-2040
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00565058
The ClinicalTrials.gov registry entry for NCT00565058 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aptose Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GTI-2040 is the first listed.
NCT00565058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00565058 about?
NCT00565058 is a clinical study titled "Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)". This is a Phase II trial conducted at multiple centers for evaluation of the pharmacodynamic activity and the overall response rate contributed by the combination agents of GTI-2040 and High Dose Cytarabine (HiDAC) in Refractory and Relapsed Acute Myeloid Leukemia (AML).
What is the current status of trial NCT00565058?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2007-08. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00565058?
The interventions under investigation include: GTI-2040 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00565058?
This trial is sponsored by Aptose Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.